PASITHEA THERAPEUTICS CORP. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent
PASITHEA THERAPEUTICS CORP. (KTTA) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent of -$13.90 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Income Statement › Net Income
us-gaap:IncomeLossFromContinuingOperations · last filed 2025-03-24
- PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2024-12-31 was -$3.18M.
- PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2024-09-30 was -$3.00M.
- PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2024-06-30 was -$3.87M.
- PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, net of tax, attributable to parent for the quarter ending 2024-03-31 was -$3.86M.
- PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2024 was -$13.90M.
- PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2023 was -$15.51M.
- PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations, net of tax, attributable to parent for fiscal 2022 was -$11.73M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 3 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 6 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 9 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$6.18M derived: sum of 2 quarters · filed 2025-03-24 | -$10.04M derived: sum of 3 quarters · filed 2025-03-24 | -$13.90M 10-K · filed 2025-03-24 |
| 2024-09-30 | -$3.00M 10-Q · filed 2024-11-13 | -$6.87M derived: sum of 2 quarters · filed 2024-11-13 | -$10.73M 10-Q · filed 2024-11-13 | -$15.76M derived: sum of 4 quarters · filed 2025-03-24 |
| 2024-06-30 | -$3.87M 10-Q · filed 2024-08-13 | -$7.73M 10-Q · filed 2024-08-13 | -$12.76M derived: sum of 3 quarters · filed 2025-03-24 | -$16.37M derived: sum of 4 quarters · filed 2025-03-24 |
| 2024-03-31 | -$3.86M 10-Q · filed 2024-05-14 | -$8.89M derived: sum of 2 quarters · filed 2025-03-24 | -$12.50M derived: sum of 3 quarters · filed 2025-03-24 | -$16.10M derived: sum of 4 quarters · filed 2025-03-24 |
| 2023-12-31 | -$5.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$8.64M derived: sum of 2 quarters · filed 2025-03-24 | -$12.24M derived: sum of 3 quarters · filed 2025-03-24 | -$15.51M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$3.61M 10-Q · filed 2024-11-13 | -$7.21M derived: sum of 2 quarters · filed 2024-11-13 | -$10.48M 10-Q · filed 2024-11-13 | -$14.53M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$3.60M 10-Q · filed 2024-08-13 | -$6.86M 10-Q · filed 2024-08-13 | -$10.92M derived: sum of 3 quarters · filed 2024-08-13 | -$15.11M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$3.27M 10-Q · filed 2024-05-14 | -$7.32M derived: sum of 2 quarters · filed 2024-05-14 | -$11.51M derived: sum of 3 quarters · filed 2024-05-14 | -$13.70M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$8.24M derived: sum of 2 quarters · filed 2024-03-29 | -$10.43M derived: sum of 3 quarters · filed 2024-03-29 | -$11.73M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$4.19M 10-Q · filed 2023-11-13 | -$6.38M derived: sum of 2 quarters · filed 2023-11-13 | -$7.67M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$2.19M 10-Q · filed 2023-08-11 | -$3.48M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | -$1.29M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |